Tamrintamab

Tamrintamab (SC-003 mAb, SC-Mab003, SC34.28ss1) is an ADC Antibody targeting to dipeptidase 3 (DPEP3 or MBD3) . DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research[1][2].

Product Specifications

CAS Number

[2148325-59-9]

Product Name Alternative

SC-003 mAb; SC-Mab003; SC34.28ss1

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tamrintamab.html

Purity

98.51

Solubility

10 mM in DMSO

Smiles

[Tamrintamab]

Molecular Weight

(146.74 kDa)

References & Citations

[1]Martín-Sabroso C, et al. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics. 2021 Oct 15;13 (10) :1705. |[2]Wiedemeyer W R, et al. Abstract NT-113: SC-003, AN ANTIBODY-DRUG CONJUGATE TARGETING DIPEPTIDASE 3, EXHIBITS POTENT ANTI-TUMOR ACTIVITY IN PATIENT-DERIVED XENOGRAFT MODELS OF HIGH GRADE SEROUS OVARIAN CANCER[J]. Clinical Cancer Research, 2019, 25 (22_Supplement) : NT-113-NT-113.